← Back to Clinical Trials
Recruiting NCT07150442

The Effects of Platelet Rich Plasma Adjuvant to Type I/III Collagen Ratio, Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Pelvic Organ Prolapse Repair

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Pelvic Organ Prolapse Vaginal Surgery
Sponsor Andalas University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 30
Sex FEMALE
Min Age 45 Years
Max Age 65 Years
Start Date 2025-08-27
Completion 2026-04
Interventions
POP surgery and PRP injectionPOP surgery and placebo injection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to analyze the effect of Platelet Rich Plasma (PRP) Adjuvant To Type I/III Colagen Ratio, MMP-2 and MMP-9 in Pelvic Organ Prolapse Repair. The main questions it aims to answer are: Does the PRP Adjuvant affect type I/III Colagen Ratio, MMP-2 and MMP-9 in Pelvic Organ Prolapse Repair? Researchers will compare patient who undergo prolapse surgery with PRP adjuvant versus patient who undergo prolapse surgery without PRP adjuvant (placeebo) Participants will: Patient will undergo pelvic organ prolapse reconstrucion surgery and punch biopsy and injection of PRP will perform in anterior vaginal mucosa at Pubocervical area. The second biopsy will attempt in 8 weeks post operative. imunohistochemistry examination will be done to compare the type I/III Colagen Ratio, MMP-2 and MMP-9 before and after surgery.

Eligibility Criteria

Inclusion Criteria: 1. Patients with second-degree or higher pelvic organ prolapse 2. Postmenopausal pelvic organ prolapse patients 3. Patients with pelvic organ prolapse who will undergo surgery 4. Willingness to participate in the study Exclusion Criteria: 1. Patients with gynecological malignancies 2. Patients with a history of collagen disease 3. Patients with blood disorders

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}